Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/-bolus therapy for Type 1 diabetes in a UK setting. An economic evaluation based on a meta-analysis of four clinical trials

被引：0

作者：

Roze, S

Palmer, AJ

Valentine, WJ

Smith, IC

Wittrup-Jensen, K

机构：

[1] CORE, Ctr Outcomes Res, Dept Stat, Binningen, Switzerland

[2] CORE, Ctr Outcomes Res, Dept Hlth Econ & Modelling, Binningen, Switzerland

[3] CORE, Ctr Outcomes Res, Dept Med Writing, Binningen, Switzerland

[4] Novo Nordisk Ltd UK, Regulatory Dept, Crawley, England

[5] Novo Nordisk AS, Global Dev Hlth Econ & Outcomes Res, DK-2880 Bagsvaerd, Denmark

来源：

DIABETOLOGIA | 2004年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

960

引用

页码：A345 / A345

页数：1

共 40 条

[31] The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting
Drummond, Russell
Malkin, Samuel
Du Preez, Michelle
Lee, Xin Ying
Hunt, Barnaby
DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2371 - 2378
[32] Fixed ratio combination insulin degludec/liraglutide (IDegLira) vs basal bolus therapy (insulin glargine-U100 plus insulin aspart) for the management of Type 2 diabetes: A short-term cost-effectiveness analysis in the UK setting
Drummond, R.
Malkin, S. J. P.
Du Preez, M.
Lee, X. Y.
Hunt, B.
DIABETIC MEDICINE, 2018, 35 : 198 - 199
[33] Efficacy and safety of basal insulin plus glucagon-like peptide-1 receptor agonist versus basal-bolus insulin in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials
Acharya, Y.
Tangney, N.
Lim, J. L.
O'Brien, T.
Liew, A.
IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 3) : 110 - 110
[34] Contribution of fasting and postprandial plasma glucose to HbA1c in people with type 2 diabetes on basal-bolus insulin: a meta-analysis of insulin lispro clinical trials
Liao, B.
Chen, Y.
Chigutsa, F.
de Oliveira, C. Piras
DIABETOLOGIA, 2020, 63 (SUPPL 1) : S332 - S332
[35] ONCE-WEEKLY ICODEC VERSUS BASAL INSULIN ANALOGS FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK: A LONG-TERM COST-EFFECTIVENESS ANALYSIS BASED ON A POST-HOC ANALYSIS OF THE ONWARDS 5 CLINICAL TRIAL
Tyagi, A.
Cattin, J.
Malkin, S.
Hunt, B.
Chubb, B.
VALUE IN HEALTH, 2024, 27 (12)
[36] Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis
Liu, Shuang
Zhao, Linbo
Shi, Fenghao
Kuai, Liping
Liu, Ruizhe
Tang, Jianhua
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (03) : 675 - 683
[37] ESTIMATING THE LONG-TERM CLINICAL AND ECONOMIC BENEFITS OF INSULIN LISPRO INTYPE I DIABETES IN THE UNITED KINGDOM: A COST-EFFECTIVENESS ANALYSIS BASED ON THE RESULTS OF A RECENT META-ANALYSIS
Smith, H. T.
Valentine, W. J.
Boye, K. S.
Kalsekar, A.
Pratoomsoot, C.
VALUE IN HEALTH, 2008, 11 (06) : A358 - A358
[38] A replication of the cost-effectiveness analysis of basal insulins in Type 1 diabetes based on the National Institute for Health and Care Excellence (NICE) NG17 methodology with the updated IMS CORE diabetes model (CDM)
Baxter, M.
Hex, N.
Mahon, J.
Schou, H.
Lee, K. C. S.
DIABETIC MEDICINE, 2018, 35 : 197 - 198
[39] COMPARISON OF TREATMENT COSTS BETWEEN BASAL-SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE (GLA) AND BOT WITH INSULIN DETEMIR (DET) IN PATIENTS WITH TYPE 2 DIABETES (T2D): ECONOMIC EVALUATION BASED ON THE RESULTS OF THE INSULIN GLARGINE (LANTUS®) VERSUS INSULIN DETEMIR (LEVEMIR®) TREAT-TO-TARGET (L2T3) STUDY
Schaedlich, P. K.
Koltermann, K. C.
Dippel, F. W.
Hagenmeyer, E. G.
Haeussler, B.
VALUE IN HEALTH, 2010, 13 (07) : A293 - A293
[40] Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis
Chen, Xi
Zhao, Mingye
Tian, Lei
FRONTIERS IN PHARMACOLOGY, 2023, 14

← 1 2 3 4 →